Abstract
Patients with primary localised prostate cancer (PCa) have a wide choice of curative therapeutic interventions, including active surveillance, surgical, focal and radiation therapies. Based on clinical and oncological characteristics, treatment decisions entail consideration of oncological and functional outcomes with important effects on quality of life. We aimed to highlight evidence surrounding present inconsistencies, the problems this presents to clinicians and patients alike and the rationale for using return to baseline as a more realistic and objective functional outcome measure for assessing sexual function in this particularly sensitive group of men. We performed a non-systematic literature review of numerous non-validated, arbitrary thresholds employed in evaluation of sexual function outcomes in men undergoing intervention for primary localised PCa. The literature presents much heterogeneity in measurement methods and outcome measures, which lack context and present difficulties when counselling patients to make informed, autonomous decisions. These include findings from the most widely used internationally validated tools, such as the International Index of Erectile Function (IIEF), UCLA prostate cancer index and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30). There is a need for standardisation of reporting outcomes following PCa treatment to facilitate evaluation of existing and emerging technologies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chiang PH, Liu YY. Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer. SpringerPlus. 2016;5:1905–1905.
Patel VR, Sivaraman A, Coelho RF, Chauhan S, Palmer KJ, Orvieto MA, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. Eur Urol. 2011;59:702–7.
Capogrosso P, Vertosick EA, Benfante NE, Eastham JA, Scardino PJ, Vickers AJ, et al. Are we improving erectile function recovery after radical prostatectomy? analysis of patients treated over the last decade. Eur Urol. 2019;75:221–8.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl J Med. 2016;375:1415–24.
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl J Med. 2016;375:1425–37.
Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Sexual rehabilitation after treatment for prostate cancer-part 1: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2017;14:285–96.
Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderang U, Thorsteinsdottir T, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial. Eur Urol. 2015;68:216–25.
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N. Engl J Med. 2013;368:436–45.
Yap T, Ahmed HU, Hindley RG, Guillaumier S, McCartan N, Dickinson L, et al. The effects of focal therapy for prostate cancer on sexual function: a combined analysis of three prospective trials. Eur Urol. 2016;69:844–51.
van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM, et al. Focal therapy in primary localised prostate cancer: the european association of urology position in 2018. Eur Urol. 2018;74:84–91.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
Albersen MJS, Van Poppel H. The use of IIEF-5 for reporting erectile dysfunction following nerve-sparing radical retropubic prostatectomy. Open Prostate Cancer J. 2009;2:1–9.
Rynja S, Bosch R, Kok E, Wouters G, de Kort L. IIEF-15: unsuitable for assessing erectile function of young men? J Sex Med. 2010;7:2825–30.
Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol. 2001;3:113–9.
Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol. 2012;62:418–30.
Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Sexual rehabilitation after treatment for prostate cancer-part 2: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med. 2017;14:297–315.
Shikanov SA, Zorn KC, Zagaja GP, Shalhav AL. Trifecta outcomes after robotic-assisted laparoscopic prostatectomy. Urology. 2009;74:619–23.
Karakiewicz PI, Tanguay S, Kattan MW, Elhilali MM, Aprikian AG. Erectile and urinary dysfunction after radical prostatectomy for prostate cancer in Quebec: a population-based study of 2415 men. Eur Urol. 2004;46:188–94.
Sridhar AN, Cathcart PJ, Yap T, Hines J, Nathan S, Briggs TP, et al. Recovery of baseline erectile function in men following radical prostatectomy for high-risk prostate cancer: a prospective analysis using validated measures. J Sex Med. 2016;13:435–43.
Blecher G, Almekaty K, Kalejaiye O, Minhas S. Does penile rehabilitation have a role in the treatment of erectile dysfunction following radical prostatectomy? F1000Res. 2017;6:1923.
Tyson MD,2nd, Koyama T, Lee D, Hoffman KE, Resnick MJ, Wu XC, et al. Effect of prostate cancer severity on functional outcomes after localized treatment: comparative effectiveness analysis of surgery and radiation study results. Eur Urol. 2018;74:26–33.
Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4:473–85.
Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, et al. The uptake of active surveillance for the management of prostate cancer: a population-based analysis. Can Urol Assoc J. 2016;10:333–8.
Gnanapragasam VJ, Thurtle D, Srinivasan A, Volanis D, George A, Lophatananon A, et al. Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. BJU Int. 2016;118:779–84.
Srougi V, Tourinho-Barbosa RR, Nunes-Silva I, Baghdadi M, Garcia-Barreras S, Rembeyo G, et al. The role of robot-assisted radical prostatectomy in high-risk prostate cancer. J Endourol. 2017;31:229–37.
Sathianathen NJ, Lamb AD, Lawrentschuk NL, Goad JR, Peters J, Costello AJ, et al. Changing face of robot-assisted radical prostatectomy in Melbourne over 12 years. ANZ J Surg. 2018;88:E200–E203.
Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res. 2002;14:245–50.
Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of erectile function. Urology. 1999;54:346–51.
Faure Walker NA, Norris JM, Shah TT, Yap T, Cathcart P, Moore CM, et al. A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. Urol Oncol. 2018;36:67–76.
Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med. 2013;10:195–203.
Capogrosso P, Ventimiglia E, Boeri L, Pozzi E, Chierigo F, Schifano N et al. Should we tailor the clinical management of erectile dysfunction according to different ages? J Sex Med. 2019;16:999–1004.
Penson DF. Time to raise the bar in localised prostate cancer. BJU Int. 2013;112:278.
Capogrosso P, Ventimiglia E, Cazzaniga W, Stabile A, Pederzoli F, Boeri L, et al. Long-term penile morphometric alterations in patients treated with robot-assisted versus open radical prostatectomy. Andrology. 2018;6:136–41.
Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Gandaglia G, et al. Depressive symptoms and low sexual desire after radical prostatectomy: early and long-term outcomes in a real-life setting. J Urol. 2018;199:474–80.
Capogrosso P, Ventimiglia E, Cazzaniga W, Montorsi F, Salonia A. Orgasmic dysfunction after radical prostatectomy. World J Mens Health. 2017;35:1–13.
Frey A, Pedersen C, Lindberg H, Bisbjerg R, Sonksen J, Fode M. Prevalence and predicting factors for commonly neglected sexual side effects to external-beam radiation therapy for prostate cancer. J Sex Med. 2017;14:558–65.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–8.
Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997;79:1977–86.
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a healthrelated quality of life measure. Med Care. 1998;36:1002–12.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.
Giesler RB, Miles BJ, Cowen ME, Kattan MW. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res. 2000;9:645–65.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.
Jayadevappa R, Chhatre S, Wong YN, Wittink MN, Cook R, Morales KH, et al. Comparative effectiveness of prostate cancer treatments for patientcentered outcomes: A systematic review and meta-analysis (PRISMA Compliant). Medicine (Baltimore). 2017;96:e6790.
Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol. 2015;68:683–91.
Nguyen LN, Head L, Witiuk K, Punjani N, Mallick R, Cnossen S, et al. The Risks and Benefits of Cavernous Neurovascular Bundle Sparing during Radical Prostatectomy: A Systematic Review and Meta-Analysis. J Urol. 2017;198:760–9.
Reeves F, Preece P, Kapoor J, Everaerts W, Murphy DG, Corcoran NM, et al. Preservation of the Neurovascular Bundles Is Associated with Improved Time to Continence After Radical Prostatectomy But Not Long-term Continence Rates: Results of a Systematic Review and Meta-analysis. European Urology. 2015;68:692–704.
Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med. 2009;6:2538–46.
Whiting PF, Moore TH, Jameson CM, Davies P, Rowlands MA, Burke M, et al. Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. BJU Int. 2016;118:193–204.
Acknowledgements
CEL is supported by an NIHR Academic Foundation Post and acknowledges support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lovegrove, C.E., Ficarra, V., Montorsi, F. et al. Sexual function outcomes following interventions for prostate cancer: are contemporary reports on functional outcomes misleading?. Int J Impot Res 32, 495–502 (2020). https://doi.org/10.1038/s41443-019-0220-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-019-0220-1
This article is cited by
-
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer
Trials (2022)
-
Sexual function and rehabilitation after radiation therapy for prostate cancer: a review
International Journal of Impotence Research (2021)
-
Neglected side effects to curative prostate cancer treatments
International Journal of Impotence Research (2021)
-
Erectile function after focal therapy for localized prostate cancer: a systematic review
International Journal of Impotence Research (2021)
-
Standardized reporting for sexual function following prostate cancer treatment
International Journal of Impotence Research (2020)